Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid
Skin Res Technol
.
2023 Oct;29(10):e13488.
doi: 10.1111/srt.13488.
Authors
Flavia Manzo Margiotta
1
,
Cristian Fidanzi
1
,
Matteo Bevilacqua
1
,
Agata Janowska
1
,
Marco Romanelli
1
,
Elisabetta Manni
1
Affiliation
1
Department of Dermatology, University of Pisa, Pisa, Italy.
PMID:
37881049
PMCID:
PMC10549962
DOI:
10.1111/srt.13488
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal, Humanized / adverse effects
Humans
Pemphigoid, Bullous* / drug therapy
Substances
dupilumab
Antibodies, Monoclonal, Humanized